spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Ruggles 

 HSMN NewsFeed - 12 Sep 2017
Cernostics Announces Leadership Team Expansion
Diagnostics Oncology Personnel
 HSMN NewsFeed - 26 Apr 2016
Intuity Medical Receives FDA Clearance to Market POGO(R) Automatic(TM) Blood Glucose Monitoring System
Diagnostics Devices Monitoring Endocrinology FDA
 HSMN NewsFeed - 26 Mar 2012
Integra LifeSciences Announces Launch of New Jarit(R) Take-Apart Laparoscopic Instruments
Devices FDA
 HSMN NewsFeed - 4 May 2011
Integra LifeSciences Announces Three-Year Contract With Novation to Provide Luxtec(R) Surgical Headlights
Devices Surgery Group Purchasing
 HSMN NewsFeed - 14 Apr 2011
Integra LifeSciences Announces Instrument Repair Partnership With InstruMedics
Devices
 HSMN NewsFeed - 4 Apr 2011
Integra LifeSciences Announces Three-Year Contract With Novation to Provide Jarit(R) Sterilization Containers
Devices Surgery Group Purchasing
 HSMN NewsFeed - 6 Dec 2010
Elan Names Robert A. Ingram Chairman-Designate
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Nov 2010
Integra LifeSciences Awarded Three Contracts With The Broadlane Group to Provide Dural Substitute, Neuro Trauma and Hydrocephalus Products
Devices Neurosurgery Group Purchasing
 HSMN NewsFeed - 15 Sep 2010
Integra LifeSciences Announces Launch of New Surgical Spine Instruments
Devices Orthopaedic Neurosurgery
 HSMN NewsFeed - 15 Mar 2010
Integra LifeSciences Introduces Four New Products at the Association of periOperative Registered Nurses (AORN) Conference
Devices Surgery
 HSMN NewsFeed - 19 Jan 2010
Integra LifeSciences Awarded Contract With HealthTrust Purchasing Group to Provide Luxtec(R) Surgical Illumination Products
Devices Group Purchasing
 HSMN NewsFeed - 28 Oct 2008
Gilead Announces Two-Year Clinical Data for Letairis(R) (ambrisentan) for the Treatment of Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals
 HSMN NewsFeed - 22 Jul 2008
Vascular Therapies LLC Appoints Samuel M. Liang as President and Chief Executive Officer
Devices Personnel
 HSMN NewsFeed - 29 May 2008
Gilead and Navitas Announce Agreement for Cicletanine for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 29 May 2008
Data from Pivotal Phase III Studies of Gilead's Letairis(R) (ambrisentan) for Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms Published in Circulation
Biopharmaceuticals
 HSMN NewsFeed - 15 May 2008
Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jan 2008
FDA Approves Cheetah Reliant(TM) for Noninvasive Cardiac Output Monitoring (NICOM(R))
Devices Cardiology Monitoring FDA
 HSMN NewsFeed - 7 Jan 2008
American Medical Systems Announces Resignation of Chief Executive Officer
Devices Personnel
 HSMN NewsFeed - 6 Nov 2007
BIOLASE Announces Management Changes
Devices Personnel
 HSMN NewsFeed - 23 Oct 2007
Gilead Announces New LetairisTM (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
U.S. Food and Drug Administration Approves Gilead's Letairis(TM) (ambrisentan) 5 mg and 10 mg Tablets for the Once-Daily Treatment of Pulmonary Arterial Hypertension (WHO Group 1) in Patients with WHO Functional Class II or III Symptoms
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2007
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
Gilead Submits New Drug Application To U.S. FDA for Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2006
Langer, Inc. Announces Resignation of Chief Financial Officer
Devices Personnel
 HSMN NewsFeed - 7 Sep 2006
Myogen Initiates Open-Label Phase 3 Clinical Trial of Ambrisentan in Patients with Pulmonary Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 4 Aug 2006
Biomet Retains Heidrick & Struggles and The McLoughlin Company to Assist in CEO Search
Devices Orthopaedic Personnel
 HSMN NewsFeed - 10 Apr 2006
Myogen Reports Positive Top Line Results for Second Ambrisentan Pivotal Phase 3 Trial in Pulmonary Arterial Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 9 Mar 2006
Ambrisentan Receives FDA Fast Track Designation for PAH Development
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Feb 2006
Myogen Reports Positive Top Line Results for Ambrisentan LFT Rescue Study In Pulmonary Arterial Hypertension
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 5

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 5 additional stories matching:
Ruggles
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.